**Specifications Table**TableSubject areaBiologyMore specific subject areaProteomics, Post-translational modificationType of dataMS data, Table, Figure,How data was acquiredMS data were acquired using data-dependent acquisition mode on a LTQ Orbitrap Velos mass spectrometer (Thermo Fisher Scientific).Data formatRaw, AnalyzedExperimental factorsDigested GPI-anchored peptides were treated with hydrogen fluoride.Experimental featuresGPI-anchored proteins were isolated from human cancer cell lines using Triton X-114 phase separation and PI-PLC treatment. The digested peptides were analyzed by nano-LC-MS/MS.Data source location*Fukuura 3-9, 8 Kanazawa, Yokohama 236-0004, Japan*Data accessibilityData is within this article and have been deposited in the ProteomeXchange Consortium (<http://proteomecentral.proteomexchange.org>) via the PRIDE partner repository with the dataset identifier PRIDE: PXD003105.

**Value of the data**•Identification of novel GPI-APs and ω-sites.•These data provide the first evidence that the GPI-anchor attaches to multiple amino acids in the C-terminal site, yielding a variety of protein species.•These data may be helpful in understanding the mechanisms of GPI anchoring.

1. Data {#s0005}
=======

We present 46 RAW mass spectrometry data files with negative controls that correspond to our LC-MS/MS analysis of 19 human cancer cell lines (ovarian cancer cell lines OVISE, A2780, OVCAR-3, OVMANA, OVSAHO, and OVSAYO, renal cancer cell lines 786-O, A498, ACHN, Caki-1, Caki-2 and UMRC3, bladder cancer cell lines 5637, T24 and UMUC3, prostate cancer cell lines DU145, LNCaP and PC3, and neuroblastoma cell line SH-SY5Y).

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository [@bib2] with the dataset identifier PRIDE: PXD003105.

2. Experimental design, materials and methods {#s0010}
=============================================

The detailed method is described elsewhere [@bib1].

2.1. Isolation of GPI-Aps {#s0015}
-------------------------

This procedure was performed as previously described [@bib3]. The GPI-AP--enriched fraction, termed the detergent-resistant membrane (DRM) fraction, was purified by sucrose gradient fractionation. The DRM fraction was resuspended in 50 mM HEPES \[pH 7.5\] and 1% (v/v) Triton X-114. This solution was subjected to Triton X-114 two-phase separation with or without Phosphatidylinositol-specific phospholipase C (PI-PLC) (from *Bacillus cereus*; Molecular-Probes USA) treatment. Supernatants were concentrated by trichloroacetic acid (TCA)/acetone precipitation and subjected to in-solution digestion (digestion with either trypsin, chymotrypsin).

2.2. GPI-APs digestion {#s0020}
----------------------

For in-solution digestion, PI-PLC treated GPI-APs were resuspended in 20 µl of 8 M urea, and dithiothreitol (DTT) was added to a final concentration of 10 mM. This mixture was incubated for 30 min at 37 °C, chilled, brought to a final concentration of 10 mM iodoacetic acid for S-alkylation, and incubated in the dark at room temperature for 15 min. After the alkylation, protein mixture was diluted with 3 volumes of 50 mM NH~4~HCO~3~ at a final concentration of 2 M urea. Proteins were digested with 0.1 µg trypsin (Trypsin Gold, MS Grade; Promega, USA) or 0.1 µg chymotrypsin (Chymotrypsin Sequencing Grade; Roche Applied Science, USA), and the sample was incubated at 37 °C for 18 h. To stop the digestion, 1 µl of 20% trifluoroacetic acid (TFA) (Wako, Japan) was added to the sample. The peptide fragments were desalted using StageTips [@bib4] with C18 Empore disk membranes (3M Company, USA) and SDB (3M Company), and then eluted with 200 µl of 60% (v/v) acetonitrile/0.1% (v/v) TFA. The eluates were immediately dried under vacuum and dissolved in 0.1% TFA.

2.3. GPI-anchored peptide enrichment and aqueous hydrogen fluoride (HF) treatment {#s0025}
---------------------------------------------------------------------------------

The GPI-anchored peptide enrichment procedure was carried out using the Titansphere Phos-TiO Kit (GL Sciences, Japan) according to the manufacturer׳s instructions. Bound GPI-anchored peptides were eluted with 50 µl of 5% NH~3~--H~2~O. Eluates were immediately dried under vacuum, and then treated with or without 20 µl of 50% (v/v) aqueous hydrogen fluoride (HF) (Wako, Japan) for 12 h at 4 °C to cleave the ethanolamine--phosphate bond. The peptide samples were again completely dried under vacuum, and then dissolved in 0.1% TFA for LC--MS/MS analysis. The negative control PI-PLC(-) or HF(-) samples from OVISE cell and SH-SY5Y cell are shown in [Table S1](#s0045){ref-type="sec"}.

2.4. Nano-LC and LTQ orbitrap velos setup {#s0030}
-----------------------------------------

Prior to injection into the mass spectrometer, The peptide samples were loaded in a reverse-phase precolumn (C18 PepMap column, LC Packings, USA) and resolved on a nanoscale C18 PepMap capillary column (75 µm id×15 cm, LC Packings, USA) at a flow rate of 300 nl/min with a gradient of acetonitrile/0.1% (v/v) formic acid. The mobile phases were solvent A (0.1% formic acid/2% (v/v) acetonitrile) and B (95% acetonitrile, 5% water, 0.1% formic acid). Peptides were separated using a linear gradient from 5% to 40% solvent B for 30 min. The full-scan mass spectra were measured from *m/z* 350--1200 in positive-ion electrospray ionization mode on a LTQ Orbitrap Velos mass spectrometer (Thermo Fisher Scientific, USA) operated in data-dependent mode and subjected to CID fragmentation using the TOP15 strategy. In brief, a scan cycle was initiated with a full scan of high mass accuracy in the Orbitrap, followed by MS/MS scans of the fifteen most intense precursor ions in the linear ion trap, with dynamic exclusion of previously selected ions. The other parameter settings were as follows: normalized collision energy, 35%; electrospray voltage, 1.8 kV; capillary temperature, 250 °C, and isolation width, 2 (*m/z*).

2.5. Data analysis {#s0035}
------------------

The raw MS spectrum was processed using Proteome Discoverer (v.1.3.0.339, Thermo Fisher Scientific), applying Mascot (v.2.4.0, Matrix Science) for peptide identification. The data were queried against UniProt/SWISS-PROT database (v2012-0711; *Homo sapiens* 20,232 sequences). All database searches were performed using a precursor mass tolerance of ±5 ppm, fragment ion mass tolerance of ±0.5 Da, enzyme name set to semi-specific trypsin or semi-specific chymotrypsin, and a maximum missed-cleavages value of 2. Oxidation of Met were set as variable modifications. Fixed modifications were set to carboxymethyl of Cys. To identify GPI-anchored peptide sequences, the EtN moiety (+43.0422 Da) was set as a variable modifications of the C-terminal peptide. As a control, carbamylation of Lys, Arg, Cys., and the N-terminus were used as variable modifications ([Table S2](#s0045){ref-type="sec"}).GPI-anchored peptide identification was considered positive when a match yielded one peptide with an ion score greater than 30 and the false-discovery rate was fixed to a threshold of 0.01 at peptide level. [Table S1](#s0045){ref-type="sec"} provides a detailed list of all identified GPI-anchored peptides from 19 human cancer cell lines along with the following additional information: accession number, gene name, enzyme used, identified peptide sequence, ion score, and molecular mass. The MS/MS spectra derived from 73 GPI-anchored peptides (EtN modified peptides) are shown in [Figure S1](#s0045){ref-type="sec"}. A detailed list of all GPI-anchored peptides identified using an FDR of 0.05 is provided in [Table S3](#s0045){ref-type="sec"}. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium (<http://proteomecentral.proteomexchange.org>) via the PRIDE partner repository [@bib2] with the dataset identifier PRIDE: PXD003105.

Appendix A. Supplementary material {#s0045}
==================================
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